4-{[({4-[(2-fluorobenzyl)oxy]-1-hydroxycyclohexyl}methyl)amino]carbonyl}phenyl acetate | 863563-81-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 4-{[({4-[(2-fluorobenzyl)oxy]-1-hydroxycyclohexyl}methyl)amino]carbonyl}phenyl acetate
• 英文别名: [4-[[4-[(2-Fluorophenyl)methoxy]-1-hydroxycyclohexyl]methylcarbamoyl]phenyl] acetate
• CAS: 863563-81-9
• 化学式: C₂₃H₂₆FNO₅
• 分子量: 415.462
• InChiKey: JPKHEDZAHKZDKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Therapeutic amide derivatives
  申请人：Kawai Makoto

  公开号：US20070167452A1

  公开（公告）日：2007-07-19

  The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.

  本发明涉及式(I)的化合物：或其药学上可接受的盐或溶剂，以及制备这些化合物的过程中使用的中间体，含有这些化合物的组合物及其作为NMDA NR2B受体拮抗剂的用途。
• THERAPEUTIC AMIDE DERIVATIVES
  申请人：Pfizer, Inc.

  公开号：EP1716100A2

  公开（公告）日：2006-11-02
• [EN] THERAPEUTIC AMIDE DERIVATIVES<br/>[FR] DERIVES D'AMIDE THERAPEUTIQUES
  申请人：PFIZER JAPAN INC

  公开号：WO2005080317A2

  公开（公告）日：2005-09-01

  The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: A and B independently represent CH2 or O, with the proviso that A and B are not simultaneously O; Cy represents one of the following Formula (II) optionally substituted by one to three groups selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy, C1-6 haloalkyl, C1-6alkylamino and amino; R1 and R2 are independently selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy, C1-6 haloalkyl and C3-8 cycloalkyl; n represents an integer from 0-4; X is hydrogen, hydroxy, halogen or C1-6alkoxy; Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy and C1-6 haloalkyl; Z is CH or N; and p represents an integer from 0-5 when Z is CH or 0-4 when Z is N; when p represents 2 or more, two of R2s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.